3 results
Approved WMOCompleted
The study is designed to evaluate the efficacy and safety of fingolimod in the treatment of CIDP compared with placebo. Data from this study will be used to support the registration of fingolimod in the indication of CIDP.
Approved WMOCompleted
The primary objective is to explore the efficacy of nintedanib (as measured by progression free survival) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.
Approved WMOPending
The primary efficacy objective for this study is to demonstrate non-inferiority of ocrelizumab compared with fingolimod